Vitamin E and Infection in the Elderly

Overview

Aging is associated with a variety of changes in the immune system. These changes result in a less effective immune response, which places the elderly at a greater risk for infection and disease. Respiratory infections cause a great number of morbidity and mortality in the elderly population. Vitamin E has been known to improve the immune response of the elderly and has been suggested for use in preventative strategies for this population. The purpose of this study is to examine the effect of one year vitamin supplementation on respiratory infection in the elderly population residing in nursing homes. This study was conducted using a randomized, double blind, placebo controlled clinical trial at 33 long-term care facilities in the greater Boston area. A total of 617 subjects over the age of 65 were enrolled in the study, with 451 completers. The participants were supplemented wit either 200 IU of vitamin E per day or placebo. The primary outcomes consisted of respiratory tract infection, number of sick days, and antibiotic use. The study involved use of questionnaires, standard anthropometrics measurements, non-invasive body composition, blood and urine sample collection, and delayed type test (DTH) using the Mantoux method. This study has been closed since August 2000 and is in the stage of data analysis only.

Study Type

  • Study Type: Interventional
  • Study Primary Completion Date: August 2001

Interventions

  • Dietary Supplement: Vitamin E
    • 200 IU alpha-tocopherol or placebo for 1 year.

Participating in This Clinical Trial

Inclusion Criteria

  • aged 65 years or older;
  • life expectancy greater than 6 months;
  • no anticipated discharge within 3 months;
  • not room-bound for the past 3 months;
  • absence of active neoplastic disease;
  • no tube feeding, no kidney dialysis;
  • no intravenous or urethral catheters for the last 30 days;
  • no tracheostomy or chronic ventilator;
  • antibiotic-free for more than 2 weeks;
  • no long-term steroid treatment greater than 10 mg/d, no use of immunosuppressive drugs, or greater than the recommended daily allowance (RDA) level of supplements of vitamins E, C, or B6, selenium, zinc, beta-carotene, or fish oil;
  • body mass index of at least 18;
  • serum albumin at least 3.0 g/dL; able to swallow pills;
  • willing to receive influenza vaccine;
  • willing to provide informed consent (for patients with dementia, family members provided informed consent)

Exclusion Criteria

Gender Eligibility: All

Minimum Age: 65 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Tufts University
  • Provider of Information About this Clinical Study
    • Simin Nikbin Meydani, DVM, PhD, Tufts University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.